^
Association details:
| Biomarker: | TNFRSF17-L |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | pavurutamab (AMG 701) (CD3 agonist, BCMA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
181 A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
Published date:
11/04/2020
Excerpt:
The response rate was 36% (16/45) at doses of 3-12 mg; at ≤1.6 mg (n=27), there was 1 response at 0.8 mg in a patient with low baseline soluble BCMA (sBCMA). Patient baseline sBCMA levels were identified as a determinant of AMG 701 free drug exposures; at higher doses, encouraging preliminary responses were seen even at the higher end of baseline sBCMA values.
Trial ID:
